Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer

Trial Profile

PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Letrozole; Paclitaxel; Tamoxifen
  • Indications Carcinoma; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms PAMELA
  • Most Recent Events

    • 04 Jun 2019 Results of a combined analysis of CALGB40601 (Alliance) and PAMELA clinical trials, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2019 Results assessing on-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome using data from NeoALTTO and validation by using data from PAMELA trial, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Sep 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top